Social Behavior – Page 14

BioMarin Appoints New R&D and Business Development Leaders

10 months ago talkbio0Tagged BioMarin, business career, development aspects, Fuchs, Greg Friberg, James, Leadership, R&D, Sabry

BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs

FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues

10 months ago talkbio0Tagged Antibodies, Bispecific, Cancer Therapeutic Procedure, Linvoseltamab, Multiple Myeloma, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment

Embracing Agility: Critical for the Role of QARA Professional

10 months ago talkbio0Tagged Access, Agility, AI, Artificial Intelligence, Communication, Diversity, Inclusion, Leadership, Market, professional occupation status, QARA, quality assurance, Regulatory Affairs, regulatory strategy, Technology

QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.

FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research

10 months ago talkbio0Tagged Clinical Trials, ethical violations, Intact, Midomafetamine, Post-Traumatic Stress Disorder, psychedelic therapy, Rejection (Psychology), Science, United States Food and Drug Administration

MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.

Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges

10 months ago talkbio0Tagged Approved, China, competition, Expiration, function, Legal patent, Nordisk, Obesity, pharmaceutical market, semaglutide, Wegovy

Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market

Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns

10 months ago talkbio0Tagged Icodec, IcoSema, Insulin, Nordisk, once-weekly, Rejection (Psychology), semaglutide, United States Food and Drug Administration

Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema

Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct

10 months ago talkbio0Tagged Clinical Research, Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, psychedelic research, Rejection (Psychology), unethical conduct, United States Food and Drug Administration

Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research

Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study

10 months ago talkbio0Tagged Discomfort, Dry Eye Syndromes, Eye, Phase 3 Clinical Trials, Rejection (Psychology), reproxalap, United States Food and Drug Administration

Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection

Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal

10 months ago talkbio0Tagged appeal, Ira (eukaryote), lawsuit, legal setback, Mediation, Medicare, Nordisk, Prices

Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal

IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest

11 months ago talkbio0Tagged Drug Industry, drug price, Economic Inflation, innovation, Ira (eukaryote), Mediation, Medicare

Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry